Skip to main content

New Research on Dantrolene

I noticed recently that a lot of the research on exon skipping has started to focus on a new, non-morpholine based compound named Dantrolene, which is currently FDA approved as a muscle relaxer.

The first few times I came across it I knew I had heard the name before, though if I'm being honest, names start to blur together at some point. I did eventually remember where it was that I had first heard of Dantrolene, though.

You're thinking about sticking this in your ryanodine receptor right now.

Little tired, so this is likely to devolve quickly, but here goes...

Where I remembered reading about Dantrolene was from [http://www.parentprojectmd.org/site/DocServer/ANAETHESIAINdmd.pdf?docID=5661](a PPMD article on anesthesia induced rhabdomyolysis). For the most part, kids with DMD are not too unlike normal kids when it comes to protocols for treatment, but there are a couple of key differentiators that you have to be aware of as a parent. One is that there is a list of inhaled anesthetics which shouldn't be administered to your kid, or he might have a bad time. I don't remember the list off hand, just that it exists (and google can do the rest). In the event of anesthesia induced rhabdo (or is it malignant hyperthermia, who knows?) doctors can prescribe Dantrolene and it may or may not help.

What's funny is I kept thinking it was some drug I read about that was being used in combination with Utrophin to hook nNOS molecules, but that must have been something else.

Pretty underwhelming stuff until you look at recent research like [https://www.ncbi.nlm.nih.gov/pubmed/23241744](this), [https://www.sciencedaily.com/releases/2012/12/121212141804.htm](this), or [http://journals.lww.com/neurotodayonline/Fulltext/2013/02070/Dantrolene_Improves_Exon_Skipping_in_Duchenne.7.aspx](this) all of which has been published in the last month. Researchers ran a screen on thousands of small molecule drugs looking for candidates and Dantrolene has emerged as a promising candidate for combination therapy with exon skipping compounds.

Pretty cool stuff, if they ever move forward with clinical trials...